FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression-Reference-Cited by-同舟云学术

FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression

Published:2019-01-10 Issue:4 Volume:19 Page:971-972
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Klintmalm Goran B.¹,Kaplan Bruce²,Kirk Allan D.³

Affiliation:

1. Baylor Annette C. and Harold C. Simmons Transplant Institute Dallas Texas

2. Transplant ServicesBaylor Scott & White Health Temple Texas

3. Department of SurgeryDuke University Durham North Carolina

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajt.15215

Reference3 articles.

1. Prescription drug benefits.Social Security Act Sec. 1860D‐2 (e)(4).https://www.ssa.gov/OP_Home/ssact/title18/1860D-02.htm. Accessed December 28 2018.

2. Payment for covered outpatient drugs.Social Security Act section 1927(k)(6).https://www.ssa.gov/OP_Home/ssact/title19/1927.htm. Accessed December 28 2018.

3. Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can Social Media Cultivate Living Organ Donors?;American Journal of Transplantation;2021-11

2. Post-transplant Medication Challenges;Challenges in Pediatric Kidney Transplantation;2021

3. Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children;Pediatric Pulmonology;2020-10-12

4. Clarifications regarding the authority and role of FDA in drug approval;American Journal of Transplantation;2020-01-07

5. Drug Policy in the Real World;American Journal of Transplantation;2019-10-28